The leadership team of pioneering biotechnology company Scancell, which is developing new immunotherapy techniques to treat cancer, announced “exciting” progress when they addressed a seminar for investors and analysts on Friday 16th February.
To view a copy of the presentation slides please see click here
Scancell, in which Calculus is the largest institutional investor, is developing lower toxicity vaccines designed to be used to help the body’s immune system fight hard to treat cancers.
The company has two technology platforms, ImmunoBody and Moditope, both of which are designed to produce vaccines that help the body’s powerful anti-cancer T-cells to identify and eliminate cancer cells.
Speaking at the Calculus-sponsored seminar at the Royal Society of Medicine in London on Friday 16th February, Scancell’s management team outlined the AIM-listed company’s latest progress, which includes:
- A partnership with Cancer Research UK (“CRUK”) in which CRUK will fund and run a clinical trial of Scancell’s ImmunoBody therapy, SCIB2, for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC).
- A research partnership with BioNTech, Europe’s largest private biotech company, with an initial focus on Scancell’s Moditope Modi-1 treatment and an eventual goal of developing new T-cell-based therapies.
- A team led by Scancell’s Chief Scientific Officer, Professor Lindy Durrant, being shortlisted for the Cancer Research UK Grand Challenge award, which provide grants for teams tackling the toughest questions in cancer research. The Modi-3 treatment generated from Scancell’s Moditope platform will be a central element of the team’s approach together with the involvement of Genentech and BioNTech.
To view the investor presentation on Youtube, click here.
To view the full unedited version on Youtube, click here